[Registration ended] [Beijing + Shanghai] Pharmaceutical Working Group Meeting: Value Creation and Strategic Risk Management in a Dynamic Environment and End-of-year Discussion Go back »
Click here to view pictures of this event.
-
Time2021-12-16 - 2021-12-16 | 14:30 - 16:00
-
Venue:European Chamber Shanghai Office
-
Address:
-
Fee:Members: Free
European Union Chamber of Commerce in China
Pharmaceutical Working Group Meeting: [Beijing + Shanghai] Value Creation and Strategic Risk Management in a Dynamic Environment and End-of-year Discussion
Date & Time: 2.30 - 4.00pm, 16th December
Venue: KPMG Office Beijing + European Chamber Shanghai Office (connected via Zoom facilities)
Registration deadline: 14th December, morning
**ONLY OPEN TO INDUSTRY MEMBERS OF THE PHARMACEUTICAL WORKING GROUP
China’s healthcare reform continues to deepen in 2021. How can multi-national pharmaceutical companies navigate these uncertain landscapes, and prepare for future?
The European Chamber Pharmaceutical Working Group is delighted to invite you to our final Working Group meeting of the year, Value Creation and Strategic Risk Management in a Dynamic Environment and End-of-year Discussion, to be held on 16th December, 2.30 – 4.00pm, at KPMG Beijing Office and European Chamber Shanghai Office.
At this meeting, Mr Frank Mei, Head of Risk Consulting at KPMG China and Ms Fran Hou, Life Science Partner at KPMG China, will share with us the latest trends in the industry and what companies need to do to better prepare themselves for an effective strategic risk management. After their presentation, Ms Li Ye, National Chair of the Pharmaceutical Working Group, will lead a free discussion on industry issues and best practices.
Agenda
2.00-2.30 Arrival and registration
2.30-2.40 Opening by Ms Li Ye, National Chair of the Pharmaceutical Working Group
2.40-3.10 Presentation by Mr Frank Mei and Ms Fran Hou of KPMG China
3.10-3.50 Free discussion led by Ms Li Ye
3.50-4.00 Closing by Ms Li Ye, National Chair of the Pharmaceutical Working Group
Please register here or reply to lshi@europeanchamber.com.cn by morning 14th December. Online attendance is also available for those who are not in Beijing or Shanghai. Please confirm whether you will attend in person or online, as we need to prepare venue according to the number of attendees.
We look forward to seeing many of you there!
Speakers
Mr. Frank Mei
Mr. Frank Mei
Frank has 25 years of advisory experience with multi-national companies and Fortune-500 Chinese in China and Asia Pacific, covering strategic risk management, business model innovation, governance strategies and operating model design, strategy development, organization transformation, compliance and internal audit. He has worked with clients from a variety of industries, including energy and resources, life science, manufacturing, and technology.
In life science industry, Frank has been serving a number of major life science clients in China and accumulated extensive experiences in helping his clients seek the optimal growth, improve business operations, design robust strategies to address industry dynamics, meet the compliance requirements, internal control and predict risk management.
Over the recent years, Frank has led the representative projects including Go-To-Market studies on innovative therapy (CAR-T, Companion diagnostic) and innovative drugs, HCP and patients’ behavior economics studies, product lifecycle management and portfolio strategy, innovative patient access pathway, digital-led business strategy development, tech-enabled operational efficiency, distributor performance assessment and risk management, strategic risk analysis and acquisition advisory based on quantitative analysis, organization transformation and China growth strategy.
Ms. Fran Hou
Ms. Fran Hou
Fran has 20 years of working experience in Life Science and FMCG industry, and worked with global leading MNC consulting firms and leading MNC manufactures. Fran has been serving a wide range of life science clients since 2008 and accumulated deep understanding of China’s life science market evolvement and the challenges & opportunities that life science companies face in China.
Over the past years, Fran has helped her clients in extensive areas of business needs diagnostic, growth opportunity identification, innovative business model development, new product launch study, tech-enabled operational efficiency, and function performance management.
Fran is the Business Development Partner of KPMG China and work with her clients including both MNC and POE to grow business in China market and optimize the growth pathway.
Ms. Ye Li
Ms. Ye Li
Ms. Li Ye is leading the Merck China Corporate Affairs hub in support to all the three business sectors (healthcare, life science &
performance materials) of Merck in China since January 2018. The China hub is among the 3 regional corporate affairs hubs (Europe, the United States and China) of Merck KGaA global wide. She is the member of the leadership team of Merck global
corporate affairs and sits in the Country Council of Merck in China. In 2021, Li Ye has been certified as a Foreign High-Level Talent of Shunyi District “Wutong Project” in Beijing.
Ms. Li Ye is a veteran in corporate affairs and government relations for international companies with her 20+ years’ working experience. She joined Merck healthcare in Aug. 2013 responsible for the government relations and market access. Prior to that, she had been taking the management roles on government affairs, market access and strategic development in top international companies including Hoechst, GlaxoSmithKline, Bayer and AstraZeneca, etc. She went to Singapore as the Regional Market Access Lead in Bayer South East Asia in 2008. Later she became Regional Payer Capabilities Director and Global Pricing
and Market Access Director for Oncology at AstraZeneca’s Asia Pacific Office until she returned to China.
Li Ye graduated from University of International Business and Economics in Beijing, then she went to the Great Britain for further study. She obtained a master’s degree in Business Administration from the University of Westminster, London. She also holds a Diploma of Economic Evaluation and Assessment in Health from the University of York, UK. In 2016, Li Ye completed her Executive MBA study in Peking University National Development School in Beijing. She is now studying for a doctorate on financial management run by the National Development School of Peking University and Fordham University in the
United States.
As an opinion leader in the industry, Li Ye also holds the positions including:
- Vice Chair of the China Association of Enterprises with Foreign Investment (CAEFI)
- Vice Chair of the China Pharmaceutical Industry Association (CPIA)
- National Chair of Research and Development Working Group, European Chamber of Commerce in China (EUCCC)